Antibody responses, amyloid-β peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 2, 2009, Pages 88-97

  Kokjohn, Tyler A ^a,b   Roher, Alex E ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; GAMMA SECRETASE INHIBITOR; HUMAN IMMUNOGLOBULIN; TAU PROTEIN; AN-1792; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; ARTICLE; ASEPTIC MENINGITIS; ASTROCYTOSIS; AUTOPSY; BRAIN HEMORRHAGE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EARLY INTERVENTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LONG TERM CARE; MENINGOENCEPHALITIS; NERVE FIBER DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; RISK BENEFIT ANALYSIS; SENILE PLAQUE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; VASCULAR AMYLOIDOSIS; WHITE MATTER; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; STATISTICS; TIME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES; CEREBRAL AMYLOID ANGIOPATHY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ACTIVE; SENILE PLAQUES; TIME; TREATMENT OUTCOME;

EID: 67049101507     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709787847315     Document Type: Article

References (56)

1. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; Michel, B.F.; Boada, M.; Frank, A.; Hock, C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003, 61, 46-54.
2. Kuo, Y.M.; Emmerling, M.R.; Vigo-Pelfrey, C.; Kasunic, T.C.; Kirkpatrick, J.B.; Murdoch, G.H.; Ball, M.J.; Roher, A.E. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem., 1996, 271, 4077-81.
3. Roher, A.E.; Chaney, M.O.; Kuo, Y.M.; Webster, S.D.; Stine, W.B.; Haverkamp, L.J.; Woods, A.S.; Cotter, R.J.; Tuohy, J.M.; Krafft, G.A.; Bonnell, B.S.; Emmerling, M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem., 1996, 271, 20631-35.
4. Heininger, K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum. Psychopharmacol., 2000, 15, 1-70.
5. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA, 1997, 94, 4109-12.
6. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C.; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400, 173-7.
7. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P.M.; Jiang, Y.; Schmidt, S.D.; Chishti, M.A.; Horne, P.; Heslin, D.; French, J.; Mount, H.T.; Nixon, R.A.; Mercken, M.; Bergeron, C.; Fraser, P.E.; St George-Hyslop, P.; Westaway, D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-82.
8. Morgan, D.; Diamond, D.M.; Gottschall, P.E.; Ugen, K.E.; Dickey, C.; Hardy, J.; Duff, K.; Jantzen, P.; DiCarlo, G.; Wilcock, D.; Connor, K.; Hatcher, J.; Hope, C.; Gordon, M.; Arendash, G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-5.
9. DeMattos, R.B.; Bales, K.R.; Cummins, D.J.; Dodart, J.C.; Paul, S.M.; Holtzman, D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 8850-5.
10. Gelinas, D.S.; DaSilva, K.; Fenili, D.; St George-Hyslop, P.; McLaurin, J. Immunotherapy for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2004, 101(Suppl 2), 14657-62.
11. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-9.
12. Puente, X.S.; Lopez-Otin, C. A genomic analysis of rat proteases and protease inhibitors. Genome Res., 2004, 14, 609-22.
13. Puente, X.S.; Sanchez, L.M.; Overall, C.M.; Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet., 2003, 4, 544-58.
14. Gandy, S.; Walker, L. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. Curr. Opin. Immunol., 2004, 16, 607-15.
15. Lemere, C.A.; Beierschmitt, A.; Iglesias, M.; Spooner, E.T.; Bloom, J.K.; Leverone, J.F.; Zheng, J.B.; Seabrook, T.J.; Louard, D.; Li, D.; Selkoe, D.J.; Palmour, R.M.; Ervin, F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 2004, 165, 283-97.
16. Kuo, Y.M.; Kokjohn, T.A.; Beach, T.G.; Sue, L.I.; Brune, D.; Lopez, J.C.; Kalback, W.M.; Abramowski, D.; Sturchler-Pierrat, C.; Staufenbiel, M.; Roher, A.E. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem., 2001, 276, 12991-8.
17. Kuo, Y.M.; Beach, T.G.; Sue, L.I.; Scott, S.; Layne, K.J.; Kokjohn, T.A.; Kalback, W.M.; Luehrs, D.C.; Vishnivetskaya, T.A.; Abramowski, D.; Sturchler-Pierrat, C.; Staufenbiel, M.; Weller, R.O.; Roher, A.E. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for A beta deposition in Alzheimer disease. Mol. Med., 2001, 7, 609-18.
18. Roher, A.E.; Kokjohn, T.A. Of mice and men: the relevance of transgenic mice Abeta immunizations to Alzheimer's disease. J. Alzheimer's Dis., 2002, 4, 431-4.
19. Kalback, W.; Watson, M.D.; Kokjohn, T.A.; Kuo, Y.M.; Weiss, N.; Luehrs, D.C.; Lopez, J.; Brune, D.; Sisodia, S.S.; Staufenbiel, M.; Emmerling, M.; Roher, A.E. APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry, 2002, 41, 922-8.
20. Esh, C.; Patton, L.; Kalback, W.; Kokjohn, T.A.; Lopez, J.; Brune, D.; Newell, A.J.; Beach, T.; Schenk, D.; Games, D.; Paul, S.; Bales, K.; Ghetti, B.; Castano, E.M.; Roher, A.E. Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides, Biochemistry, 2005, 44, 13807-19.
21. Van Vickle, G.D.; Esh, C.L.; Kalback, W.M.; Patton, R.L.; Luehrs, D.C.; Kokjohn, T.A.; Fifield, F.G.; Fraser, P.E.; Westaway, D.; McLaurin, J.; Lopez, J.; Brune, D.; Newel, A.J.; Poston, M.; Beach, T.G.; Roher, A.E. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. Biochemistry, 2007, 46, 10317-27.
22. Van Vickle, G.D.; Esh, C.L.; Daugs, I.D.; Kokjohn, T.A.; Kalback, W.M.; Patton, R.L.; Luehrs, D.C.; Walker, D.G.; Lue, L.F.; Beach, T.G.; Davis, J.; Van Nostrand, W.E.; Castano, E.M.; Roher, A.E. Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am. J. Pathol., 2008, 173, 483-93.
23. Games, D.; Adams, D.; Alessandrini, R.; Barbour, R.; Berthelette, P.; Blackwell, C.; Carr, T.; Clemens, J.; Donaldson, T.; Gillespie, F.; Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature, 1995, 373, 523-7.
24. Roher, A.E.; Kokjohn, T.A.; Esh, C.; Weiss, N.; Childress, J.; Kalback, W.; Luehrs, D.C.; Lopez, J.; Brune, D.; Kuo, Y.M.; Farlow, M.; Murrell, J.; Vidal, R.; Ghetti, B. The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. J. Biol. Chem., 2004, 279, 5829-36.
25. Nicoll, J.A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.; Weller, R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 2003, 9, 448-52.
26. Ferrer, I.; Boada, R.M.; Sanchez G.M.L.; Rey, M.J.; Costa-Jussa, F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease, Brain Pathol., 2004, 14, 11-20.
27. Masliah, E.; Hansen, L.; Adame, A.; Crews, L.; Bard, F.; Lee, C.; Seubert, P.; Games, D.; Kirby, L.; Schenk, D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64, 129-31.
28. Patton, R.L.; Kalback, W.M.; Esh, C.L.; Kokjohn, T.A.; Van Vickle, G.D.; Luehrs, D.C.; Kuo, Y.M.; Lopez, J.; Brune, D.; Ferrer, I.; Masliah, E.; Newel, A.J.; Beach, T.G.; Castano, E.M.; Roher, A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol., 2006, 169, 1048-63.
29. Nicoll, J.A.; Barton, E.; Boche, D.; Neal, J.W.; Ferrer, I.; Thompson, P.; Vlachouli, C.; Wilkinson, D.; Bayer, A.; Games, D.; Seubert, P.; Schenk, D.; Holmes, C. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol., 2006, 65, 1040-8.
30. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-23.
31. Roher, A.E.; Palmer, K.C.; Yurewicz, E.C.; Ball, M.J.; Greenberg, B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J. Neurochem., 1993, 61, 1916-26.
32. Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; Paul, S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci., 2002, 5, 452-7.
33. Hock, C.; Konietzko, U.; Papassotiropoulos, A.; Wollmer, A.; Streffer, J.; von Rotz, R.C.; Davey, G.; Moritz, E.; Nitsch, R.M. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med., 2002, 8, 1270-5.
34. Lee, M.; Bard, F.; Johnson-Wood, K.; Lee, C.; Hu, K.; Griffith, S.G.; Black, R.S.; Schenk, D.; Seubert, P. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann. Neurol., 2005, 58, 430-5.
35. McLaurin, J.; Cecal, R.; Kierstead, M.E.; Tian, X.; Phinney, A.L.; Manea, M.; French, J.E.; Lambermon, M.H.; Darabie, A.A.; Brown, M.E.; Janus, C.; Chishti, M.A.; Horne, P.; Westaway, D.; Fraser, P.E.; Mount, H.T.; Przybylski, M.; St George-Hyslop, P. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med., 2002, 8, 1263-9.
36. Roher, A.E.; Weiss, N.; Kokjohn, T.A.; Kuo, Y.M.; Kalback, W.; Anthony, J.; Watson, D.; Luehrs, D.C.; Sue, L.; Walker, D.; Emmerling, M.; Goux, W.; Beach, T. Increased Abeta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry, 2002, 41, 11080-90.
37. Roher, A.E.; Kuo, Y.M.; Esh, C.; Knebel, C.; Weiss, N.; Kalback, W.; Luehrs, D.C.; Childress, J.L.; Beach, T.G.; Weller, R.O.; Kokjohn, T.A. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol. Med., 2003, 9, 112-22.
38. Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004, 43, 321-32.
39. Greenberg, S.M.; Bacskai, B.J.; Hyman, B.T. Alzheimer disease's double-edged vaccine. Nat. Med., 2003, 9, 389-90.
40. Furlan, R.; Brambilla, E.; Sanvito, F.; Roccatagliata, L.; Olivieri, S.; Bergami, A.; Pluchino, S.; Uccelli, A.; Comi, G.; Martino, G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain, 2003, 126, 285-91.
41. Lee, E.B.; Leng, L.Z.; Lee, V.M.; Trojanowski, J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett., 2005, 579, 2564-8.
42. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L.A.; Milton, S.; Glabe, C.; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28, 3555-66.
43. Hock, C.; Konietzko, U.; Streffer, J.R.; Tracy, J.; Signorell, A.; Muller-Tillmanns, B.; Lemke, U.; Henke, K.; Moritz, E.; Garcia, E.; Wollmer, M.A.; Umbricht, D.; de Quervain, D.J.; Hofmann, M.; Maddalena, A.; Papassotiropoulos, A.; Nitsch, R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 2003, 38, 547-54.
44. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; Orgogozo, J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-62.
45. Fox, N.C.; Black, R.S.; Gilman, S.; Rossor, M.N.; Griffith, S.G.; Jenkins, L.; Koller, M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005, 64, 1563-72.
46. Josephs, K.A.; Whitwell, J.L.; Ahmed, Z.; Shiung, M.M.; Weigand, S.D.; Knopman, D.S.; Boeve, B.F.; Parisi, J.E.; Petersen, R.C.; Dickson, D.W.; Jack, C.R., Jr. Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol., 2008, 63, 204-12.
47. Das, P.; Murphy, M.P.; Younkin, L.H.; Younkin, S.G.; Golde, T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging, 2001, 22, 721-7.
48. Klunk, W.E.; Price, J.C.; Mathis, C.A.; Tsopelas, N.D.; Lopresti, B.J.; Ziolko, S.K.; Bi, W.; Hoge, J.A.; Cohen, A.D.; Ikonomovic, M.D.; Saxton, J.A.; Snitz, B.E.; Pollen, D.A.; Moonis, M.; Lippa, C.F.; Swearer, J.M.; Johnson, K.A.; Rentz, D.M.; Fischman, A.J.; Aizenstein, H.J.; DeKosky, S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci., 2007, 27, 6174-84.
49. Meyer-Luehmann, M.; Spires-Jones, T.L.; Prada, C.; Garcia-Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature, 2008, 451, 720-4.
50. Roher, A.E.; Lowenson, J.D.; Clarke, S.; Woods, A.S.; Cotter, R.J.; Gowing, E.; Ball, M.J. Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90, 10836-40.
51. Pfeifer, M.; Boncristiano, S.; Bondolfi, L.; Stalder, A.; Deller, T.; Staufenbiel, M.; Mathews, P.M.; Jucker, M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science, 2002, 298, 1379.
52. Wilcock, D.M.; Jantzen, P.T.; Li, Q.; Morgan, D.; Gordon, M.N. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience, 2007, 144, 950-60.
53. Kotilinek, L.A.; Bacskai, B.; Westerman, M.; Kawarabayashi, T.; Younkin, L.; Hyman, B.T.; Younkin, S.; Ashe, K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci., 2002, 22, 6331-5.
54. Heininger, K. A unifying hypothesis of Alzheimer's disease. IV: causation and sequence of events, Rev. Neurosci., 2000, 11(Spec No), 213-328.
55. Relkin, N.R.; Szabo, P.; Adamiak, B.; Burgut, T.; Monthe, C.; Lent, R.W.; Younkin, S.; Younkin, L.; Schiff, R.; Weksler, M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging, 2008.
56. Miravalle, L.; Calero, M.; Takao, M.; Roher, A.E.; Ghetti, B.; Vidal, R. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry, 2005, 44, 10810-21.